The similarities and differences in socio-demographic characteristics of the OCP acceptors in the two study groups are shown in Table 1. Mean age of each of the 3G-OCP and 2G-OCP acceptors was 29 years. When comparing the educational status, about 60% of the OCP acceptors in both the groups had at least incomplete secondary or higher education. Only 4% of the acceptors in the intervention group and 6% in the control group had no education. About 47% of the husbands from each group of OCP acceptors had incomplete secondary or higher education. About 10% of the husbands of 3G-OCP users as compared to 14% of those accepting 2G-OCP had no education. For the employment status of the OCP acceptors, only about 5% in each intervention and control group were involved with any income-generating activities. The OCP acceptors in the control group had relatively higher monthly family expenditure as compared to that in the intervention area (Taka 11,644 vs. Taka 11,575 equivalent to USD 137 vs. USD 136). About 2–3% of the OCP acceptors had a monthly family expenditure less than or equal to Taka 5,000 (equivalent to USD 59). Almost all of the women (over 99%) in each intervention and control group reported using a contraceptive method previously. Only 0.1% of the women in the intervention group and 0.3% in the control group did not use any contraceptive method previously. Among the women who mentioned using a contraceptive method, about 97% in both the intervention and control groups had taken oral pills previously. A substantial proportion of women (51% in the intervention and 41% in control union) had used injectable contraceptive. Among the other types of contraceptive methods, in the intervention area, about 20% reported using both the condom and maintaining safe period methods. On the other hand, in the control area, 45% of the women practiced safe period and 11% used condom.
Table 1
Variations in socio-demographic characteristics of the of the OCP acceptors by type
Socio-demographic characteristics
|
% of OCP acceptors by type
|
Total
n = 2800
|
3G-OCP
n = 1400
|
2G-OCP
n = 1400
|
Age (in years) of the clients
|
<= 19
|
8.4
|
8.8
|
8.0
|
20–24
|
21.2
|
20.4
|
22.1
|
25–29
|
20.0
|
18.9
|
21.1
|
30–34
|
20.6
|
22.4
|
18.8
|
35–39
|
29.8
|
29.6
|
30.0
|
Mean (SD)
|
29.1(6.7)
|
29.1(6.7)
|
29.0(6.7)
|
t = 0.58 p = 0.559
|
|
|
|
Educational status of the clients
|
No education
|
4.8
|
4.1
|
5.5
|
Incomplete primary
|
10.1
|
13.9
|
6.3
|
Completed primary
|
25.6
|
22.4
|
28.9
|
Incomplete secondary
|
44.0
|
45.1
|
42.9
|
Completed secondary
|
8.8
|
8.0
|
9.5
|
Higher than secondary
|
6.7
|
6.4
|
7.0
|
χ2 = 56.77 p < 0.001
|
|
|
|
Employment status of the clients
|
Nothing
|
95.4
|
94.9
|
95.9
|
Formal Job
|
1.9
|
1.4
|
2.4
|
Informal Job
|
2.7
|
3.6
|
1.7
|
χ2 = 12.98 p < 0.001
|
|
|
|
Education of husband of the clients
|
No education
|
11.7
|
9.6
|
13.7
|
Incomplete primary
|
12.5
|
17.4
|
7.6
|
Completed primary
|
28.7
|
26.0
|
31.5
|
Incomplete secondary
|
27.8
|
29.0
|
26.6
|
Completed secondary
|
9.1
|
8.3
|
9.9
|
Higher than secondary
|
10.2
|
9.6
|
10.8
|
χ2 = 75.89 p < 0.001
|
|
|
|
Monthly family expenditure of the clients (in Taka)
|
<= 5000
|
2.2
|
1.9
|
2.6
|
5001–10000
|
52.7
|
52.4
|
53.0
|
10001–15000
|
30.2
|
30.4
|
30.1
|
15001–20000
|
9.7
|
9.4
|
10.0
|
20000+
|
3.6
|
3.1
|
4.1
|
Didn’t know
|
1.6
|
2.9
|
0.3
|
χ2 = 34.041 p < 0.001
|
|
|
|
Mean (SD)
|
11610.5 (4836.3)
|
11575.4 (4649.9)
|
11644.7
|
Ever used any contraceptive method
|
Yes
|
99.8
|
99.9
|
99.7
|
No
|
0.2
|
0.1
|
0.3
|
χ2 = 1.80 p = 0.179
|
|
|
|
Type of method ever used (Multiple Response)
|
n = 2794
|
n = 1399
|
n = 1395
|
Oral pill
|
96.8
|
96.8
|
96.8
|
Injectables
|
46.0
|
51.0
|
40.9
|
Condom
|
15.5
|
19.7
|
11.3
|
IUD
|
1.4
|
0.9
|
1.8
|
Implant/Norplant
|
2.6
|
3.4
|
1.9
|
Safe period
|
32.4
|
19.9
|
44.9
|
Refuse to answer
|
0.1
|
0.0
|
0.1
|
Withdrawal
|
2.4
|
4.2
|
0.6
|
OCP = Oral Contraceptive Pill, 3G-OCP = Third Generation Oral Contraceptive Pill, 2G-OCP = Second Generation Oral Contraceptive Pill, SD = Standard Deviation, IUD = Intra Uterine Device |
Profile of side effects of 3G-OCP and 2G-OCP users
The incidence of different reported side-effects between the 3G-OCP and 2G-OCP acceptors at different time points during the 6-month follow-up period of the study is shown in Table 2. Initially, the 3G-OCP acceptors reported a higher incidence of side-effects (47.3%) as compared to the 2G-OCP acceptors (33.2%). However, at the end of 6 months of use, the incidence of reported side-effects of the two types of OCPs in the study convened to about 9%.
Direct pill use related problems
The analysis noted a significantly higher incidence of any direct pill use related problem among the 3G-OCP users as compared to 2G-OCP users in the first four months of follow-up. However, in the 5th and 6th months this variation deteriorated. Nevertheless, in the 6th-month follow-up, the 2G-OCP users reported a higher incidence of vertigo and nausea as compared to the corresponding figures by 3G-OCP users. In the 6th-month, any direct pill use related problem by the 3G-OCP users was even lower (4.7%) than the reported figure by the 2G-OCP users (6.0%), though the difference was not statistically significant (Table 2).
Table 2: Comparison of side-effects related to use of OCP type at different time points of use
|
|
% of OCP acceptors by type had side-effects after use of months
|
Type of side effects
|
At 1 month
|
At 3 month
|
At 6 month
|
3G-OCP
n=1315
|
2G-OCP
n=1205
|
3G-OCP
n=1022
|
2G-OCP
n=913
|
3G-OCP
n=970
|
2G-OCP
n=816
|
Direct pill use related
|
|
Headache
|
2.0
|
3.3
|
0.5
|
0.4
|
0.0
|
0.1
|
Vertigo
|
35.6
|
26.4
|
11.3
|
6.1
|
2.6
|
4.4
|
Nausea
|
17.9
|
19.5
|
3.2
|
3.0
|
2.0
|
4.7
|
Weight gain
|
0.4
|
1.2
|
0.0
|
0.3
|
|
|
Acne in face
|
0.2
|
0.0
|
0.0
|
0.0
|
0.1
|
0.0
|
Growth of unwanted hair
|
0.0
|
0.0
|
0.0
|
0.0
|
|
|
Spottings
|
0.4
|
0.1
|
0.1
|
0.0
|
|
|
Menstrual bleeding less than normal
|
1.0
|
1.3
|
1.0
|
1.3
|
1.0
|
0.2
|
Cessation of menstruation
|
0.8
|
0.5
|
0.6
|
0.1
|
|
|
Migraine
|
2.1
|
0.8
|
0.0
|
0.0
|
|
|
Prolonged duration of menstruation
|
0.8
|
0.4
|
0.1
|
0.0
|
|
|
High blood pressure
|
0.5
|
1.4
|
0.2
|
0.1
|
0.2
|
0.0
|
Excessive vomiting
|
1.9
|
0.7
|
0.3
|
0.0
|
|
|
Any direct pill use related
|
41.0
|
31.0
|
14.9
|
8.9
|
4.7
|
6.0
|
Probable pill use related
|
|
White discharge
|
5.6
|
3.2
|
4.3
|
2.5
|
2.7
|
1.3
|
Excessive bleeding during menstruation
|
2.4
|
0.2
|
1.4
|
0.1
|
0.7
|
0.0
|
Blurred vision
|
3.5
|
4.4
|
0.6
|
0.2
|
0.8
|
0.1
|
Varicose vein
|
0.2
|
0.2
|
0.0
|
0.0
|
|
|
Dried breast milk
|
0.3
|
0.2
|
0.1
|
0.2
|
|
|
Yellowish eyes/urine
|
0.1
|
0.0
|
0.0
|
0.0
|
|
|
Any probable pill use related
|
11.1
|
7.4
|
6.2
|
3.0
|
3.9
|
1.5
|
Possible pill use related
|
|
Weakness
|
11.4
|
8.3
|
2.7
|
1.5
|
2.4
|
3.6
|
Lower abdominal pain
|
0.9
|
1.2
|
0.1
|
0.1
|
0.2
|
0.6
|
Heaviness on foot/pain in leg
|
0.4
|
0.0
|
0.0
|
0.0
|
0.1
|
0.0
|
Frequent urination
|
0.8
|
0.4
|
0.4
|
0.0
|
0.0
|
0.1
|
Acidity/Gastric
|
1.8
|
0.3
|
1.6
|
0.1
|
1.2
|
0.1
|
Varicose vein
|
0.2
|
0.2
|
0.0
|
0.0
|
|
|
Chest pain
|
0.1
|
0.2
|
0.0
|
0.0
|
|
|
Any possible pill use related
|
13.8
|
9.6
|
4.5
|
1.8
|
3.9
|
4.3
|
Other health problems
|
|
Back pain
|
0.2
|
0.1
|
0.0
|
0.1
|
0.0
|
0.0
|
Breathing difficulties
|
0.3
|
0.2
|
0.3
|
0.0
|
0.0
|
0.0
|
Others
|
1.1
|
0.9
|
0.2
|
0.4
|
0.0
|
0.0
|
Any other health problem
|
1.7
|
1.2
|
0.5
|
0.5
|
0.0
|
0.0
|
Any side-effect or health problem
|
47.3
|
33.2
|
21.6
|
11.5
|
9.5
|
8.7
|
Significant at 5% level for t test for proportions between 3G-OCP and 2G-OCP
|
OCP=Oral Contraceptive Pill, 3G-OCP=Third Generation Oral Contraceptive Pill, 2G-OCP=Second Generation Oral Contraceptive Pill
Probable pill use related problems
Comparison of reported probable pill use related problems showed an overall decline in reported side-effects in both groups of OCP users (reduced from 11.1–3.9% in 3G-OCP and 7.4–1.5% in 2G-OCP users). However, overall, there was a persistent higher incidence of related side-effects among the 3G-OCP users than the 2G-OCP users. When analyzed by types of side-effects, white discharge, excessive bleeding and blurred vision were significantly higher in the 3G-OCP users than those using 2G-OCP (Table 2).
Possible pill use related problems
Our analysis demonstrates a higher incidence of any possible pill use related problem in 3G-OCP users than those using the 2G-OCP in each of the first four-month time points consecutively. However, at the 5th and 6th month time point this variation was eliminated (Table 2).
Other health problems
Overall reporting of other health problems was low (ranging from 1.2–1.7%) in the first follow-up that gradually reduced to 0% at 6 months of use (Table 2). No variation in other reported health problems between 3G-OCP and 2G-OCP users was observed over time.
Status of continuation with 3G-OCP and 2G-OCPs
Among the enrolled women in both intervention and control groups, 967 (69.1%) and 812 (58.0%) continued with taking the OCPs respectively at the end of 6-month follow-up (Fig. 1). The crude discontinuation rates due to side-effects were 20.4% (n = 285) and 19.5% (n = 273) for 3G-OCP and 2G-OCPs respectively. A substantial proportion of subjects in each intervention (9.0%, n = 126) and control (18.1%, n = 254) group, discontinued the method due to various social reasons (husband’s disapproval, husband away, wanted child were the top three reasons for method discontinuation) (Table 3). During the 6-month follow-up period, 4 women in the intervention group and 7 in the control group reported getting pregnant. When these women were asked about the reasons for becoming pregnant, the majority (75.0% in the intervention and 57.1% in the control group) said about stopping the pill due to side-effects. About one-fourth of the women in each intervention and control group mentioned forgetting taking the pill as a reason for becoming pregnant (Table 3).
Table 3
Reasons for discontinuation of OCP by type at different follow-up visits
Reasons for discontinuation
|
% (number) discontinued by at different follow-up visits by type of OCP used
|
At 3 month follow-up
|
At 6 month follow-up
|
Overall
|
3G-OCP
n = 1400
|
2G-OCP
n = 1400
|
3G-OCP
n = 1015
|
2G-OCP
n = 906
|
3G-OCP
n = 1400
|
2G-OCP
n = 1400
|
Side-effects
|
18.0
(252)
|
17.8
(249)
|
3.3
(33)
|
2.6
(24)
|
20.4
(285)
|
19.5
(273)
|
Social reasons
|
8.4
(118)
|
14.6
(205)
|
0.8
(8)
|
5.4
(49)
|
9.0
(126)
|
18.1
(254)
|
Became pregnant due to stopped taking pill
|
0.2
(3)
|
0.5
(7)
|
0.1
(1)
|
0.0
(0)
|
0.3
(4)
|
0.5
(7)
|
Death
|
0.0
(0)
|
0.1
(1)
|
0.1
(1)
|
0.1
(1)
|
0.1
(1)
|
0.1
(2)
|
Lost to follow-up
|
0.9
(12)
|
2.3
(32)
|
0.5
(5)
|
2.2
(20)
|
1.2
(17)
|
3.7
(52)
|
Any reason
|
27.5
(385)
|
35.3
(494)
|
4.7
(48)
|
19.4
(94)
|
30.9
(433)
|
42.0
(588)
|
OCP = Oral Contraceptive Pill, 3G-OCP = Third Generation Oral Contraceptive Pill, 2G-OCP = Second Generation Oral Contraceptive Pill |
Life table analysis for discontinuation of OCP
The discontinuation rate of the 3G-OCP was 2.4% lower than that of 2G-OCP. Results from the life table analysis, after taking into account the duration of OCP use revealed that by the end of 24 weeks, discontinuation rate attributed to side-effects of the 2G-OCP was 25.2% as compared to 22.8% for the 3G-OCP. However, this difference was not statistically significant (Fig. 2). The same analysis also showed that the major share of these discontinuations occurred within the first 4 weeks of OCP adherence (14.6% for 3G-OCP and 19.6% for 2G-OCP).
Reasons for discontinuation of OCP due to side-effects
Table 4 demonstrates the proportion of women who discontinued OCP due to various side-effects. Most of the side-effect related discontinuations occurred within the first follow-up visit for both the groups of women. At the end of the first follow-up visit, among the women who discontinued OCP, over 90% in both intervention and control groups discontinued the method use due to direct pill use related problem in which vertigo, nausea, excessive vomiting and migraine were the major reasons for discontinuation. At the end of the first follow-up visit, about a quarter of the participants (25.0% in the intervention and 27.7% in the control group), reported discontinuing the OCP due to a probable pill use related problem in which blurred vision, excessive bleeding during menstruation and white discharge were major reported reasons. At the end of the first follow-up visit, 13.1% and 14.5% of the discontinuations for the 3G-OCP and 2G-OCP respectively were due to any possible pill use related problem in which lower abdominal pain, acidity/gastric, weakness, and frequent urination were the main problems. Other health problems such as loss of appetite, breathing difficulties, back pain etc. were reported by around 4% of the women from in each intervention and control group as reasons for discontinuing the method use.
Table 4
Reasons for discontinuation due to side-effects by type of OCP used by follow-up visits
Reasons for discontinuation
|
% discontinued at follow-up visits by type of OCP used
|
At 3 month follow-up
|
At 6 month follow-up
|
3G-OCP
n = 252
|
2G-OCP
n = 249
|
3G-OCP
n = 33
|
2G-OCP
n = 24
|
Direct pill use related
|
Vertigo
|
86.9
|
84.3
|
93.9
|
66.7
|
Nausea
|
63.9
|
72.3
|
84.8
|
70.8
|
Excessive vomiting
|
11.1
|
6.0
|
3.0
|
0.0
|
Migraine
|
9.5
|
8.0
|
6.1
|
0.0
|
Prolonged duration of menstruation
|
5.2
|
2.4
|
|
|
High blood pressure
|
2.0
|
5.6
|
|
|
Weight gain
|
1.2
|
4.8
|
0.0
|
16.7
|
Cessation of menstruation
|
1.2
|
2.0
|
3.0
|
0.0
|
Irregular menstrual bleeding
|
0.0
|
1.2
|
|
|
Menstrual bleeding less than normal
|
0.0
|
0.8
|
|
|
Any direct pill use related
|
94.4
|
97.2
|
100.0
|
87.5
|
Probable pill use related
|
Blurred vision
|
15.1
|
20.9
|
18.2
|
4.2
|
Excessive bleeding during menstruation
|
5.6
|
1.6
|
|
|
White discharge
|
5.2
|
5.2
|
15.2
|
4.2
|
Dried breast milk
|
1.2
|
1.2
|
|
|
Insomnia
|
0.4
|
0.0
|
|
|
Dementia/Depression
|
0.0
|
0.4
|
|
|
Jaundice
|
0.0
|
0.4
|
|
|
Any probable pill use related
|
25.0
|
27.7
|
27.3
|
4.2
|
Possible pill use related
|
Lower abdominal pain
|
4.0
|
4.8
|
3.0
|
8.3
|
Acidity/Gastric
|
2.8
|
1.2
|
9.1
|
0.0
|
Weakness
|
2.4
|
6.0
|
|
|
Frequent urination
|
2.4
|
1.6
|
3.0
|
0.0
|
Chest pain
|
0.8
|
0.4
|
|
|
Pain in leg
|
0.8
|
0.0
|
|
|
Tumor in uterus
|
0.0
|
0.4
|
|
|
Difficulty in urination
|
0.0
|
0.4
|
|
|
Heaviness on foot
|
0.4
|
0.0
|
|
|
Any possible pill use related problem
|
13.1
|
14.5
|
12.1
|
8.3
|
Other health problems
|
Loss of appetite
|
1.2
|
0.8
|
|
|
Breathing difficulties
|
0.0
|
2.0
|
0.0
|
4.2
|
Back pain
|
2.0
|
0.0
|
|
|
Allergy
|
0.4
|
0.4
|
|
|
Tumor in hand
|
0.0
|
0.4
|
|
|
Any other health problem
|
3.6
|
3.6
|
0.0
|
4.2
|
OCP = Oral Contraceptive Pill, 3G-OCP = Third Generation Oral Contraceptive Pill, 2G-OCP = Second Generation Oral Contraceptive Pill |
The study also observed 3 deaths, 1 in the intervention area and 2 in the control group. The death in the intervention group was due to diarrhoea and therefore not likely to be related to the use of 3G-OCP under this study. Of the two death cases in the control group, one was due to a stroke that was likely to be related to the use of 2G-OCP. The other death case in the control group had pre-existing kidney and heart disease and a history of taking 2G-OCP. Despite being enrolled in the study, the latter woman did not use the 2G-OCP in the current study thus this death was not related to the study intervention.
Cox-Hazard model for discontinuation of OCPs
In this study, we fitted Cox’s Proportional Hazard model to estimate the Hazard Ratio (HR) for discontinuation of type of OCP adjusted for selected socio-demographic covariates (client’s age, educational status, employment status, previously used OCP as a contraceptive method, women’s husbands’ educational level and monthly family expenditure). Table 5 demonstrates that after adjusting for socio-demographic covariates, the 3G-OCP users were 14% less likely to discontinue the method as compared to those using the 2G-OCP (HR = 0.86, p = 0.075) which was statistically significant at 10% level of error. We also observed that women with increasing age, low education level, previous use of OCP, and low family income were more likely to discontinue OCP (Table 5).
Table 5
Crude and adjusted HRs with 95% CIs for discontinuation of 2G-OCP as compared to 3G-OCP adjusted for different covariates
Covariates
|
n
|
Crude
|
Adjusted
|
HRs
|
95.0% CI
|
p- value
|
HRs
|
95.0% CI
|
p-value
|
Type of OCP used
|
2G-OCP
|
1085
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
3G-OCP
|
1252
|
0.89
|
0.75–1.05
|
0.15
|
0.86
|
0.72–1.02
|
0.08
|
Age (in years) of the clients
|
<= 19
|
168
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
20–24
|
487
|
0.78
|
0.56–1.08
|
0.14
|
0.78
|
0.56–1.09
|
0.14
|
25–29
|
457
|
0.74
|
0.53–1.04
|
0.08
|
0.75
|
0.53–1.06
|
0.10
|
30–34
|
507
|
0.71
|
0.51–0.99
|
0.04
|
0.73
|
0.52–1.02
|
0.06
|
35–39
|
718
|
0.70
|
0.51–0.96
|
0.03
|
0.74
|
0.53–1.03
|
0.07
|
Educational status of the clients
|
No education
|
116
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
Incomplete primary
|
248
|
1.57
|
0.91–2.70
|
0.11
|
1.59
|
0.91–2.77
|
0.10
|
Primary
|
622
|
1.83
|
1.11–3.03
|
0.02
|
1.77
|
1.06–2.95
|
0.03
|
Incomplete secondary
|
990
|
1.78
|
1.09–2.92
|
0.02
|
1.69
|
1.00-2.85
|
0.05
|
Secondary
|
204
|
1.56
|
0.89–2.72
|
0.12
|
1.43
|
0.78–2.61
|
0.25
|
Higher
|
157
|
2.03
|
1.16–3.55
|
0.01
|
2.02
|
1.06–3.86
|
0.03
|
Employment status of the clients
|
Nothing
|
2225
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
Formal job
|
48
|
0.84
|
0.45–1.57
|
0.58
|
0.62
|
0.30–1.26
|
0.18
|
Informal job
|
64
|
0.98
|
0.59–1.64
|
0.94
|
1.04
|
0.62–1.74
|
0.90
|
Education status of the husbands of the clients
|
No education
|
282
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
Incomplete primary
|
307
|
1.22
|
0.87–1.71
|
0.26
|
1.19
|
0.84–1.69
|
0.33
|
Primary
|
688
|
1.18
|
0.88–1.59
|
0.28
|
1.06
|
0.78–1.45
|
0.69
|
Incomplete secondary
|
628
|
1.12
|
0.83–1.52
|
0.46
|
1.01
|
0.73–1.40
|
0.95
|
Secondary
|
201
|
1.15
|
0.78–1.68
|
0.49
|
1.05
|
0.69–1.59
|
0.84
|
Higher
|
231
|
1.32
|
0.92–1.88
|
0.13
|
1.20
|
0.78–1.85
|
0.41
|
Monthly family expenditure (in Taka)
|
<= 5000
|
54
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
5001–10000
|
1226
|
1.72
|
0.85–3.46
|
0.13
|
1.81
|
0.89–3.65
|
0.10
|
10001–15000
|
713
|
1.60
|
0.79–3.26
|
0.19
|
1.69
|
0.83–3.44
|
0.15
|
15001–20000
|
224
|
1.72
|
0.82–3.62
|
0.15
|
1.75
|
0.83–3.69
|
0.14
|
20000+
|
81
|
2.28
|
1.03–5.07
|
0.04
|
2.38
|
1.06–5.34
|
0.04
|
Didn’t Know
|
39
|
3.10
|
1.33–7.24
|
0.01
|
3.25
|
1.38–7.64
|
0.01
|
Previously used OCP
|
Yes
|
2258
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
No
|
79
|
1.28
|
0.84–1.94
|
0.25
|
1.29
|
0.85–1.97
|
0.23
|
HRs = Hazard Ratios, CIs = Confidence Intervals, 2G-OCP = Second Generation Oral Contraceptive Pill, 3G-OCP = Third Generation Oral Contraceptive Pill, OCP = Oral Contraceptive Pills |